Global Kinetics Brings In Big Investments In Parkinson's Tracker
Global Kinetics has launched the global randomized Treat-to-Target trial of its Personal KinetiGraph Parkinson's disease monitor. This comes a few days after the publication of a a clinical trial showing how monitoring Parkinson's symptoms with the device can lead to improvements in patients' therapy.
You may also be interested in...
Global Kinetics’ Personal KinetiGraph Identifies Parkinson’s Patients Suitable For Deep Brain Stimulation
A new study shows the Personal KinetiGraph wearable monitor can help clinicians identify the Parkinson’s disease patients most likely to benefit from device-assisted therapies, including deep brain stimulation.
Results Recap: Personal KinetiGraph Provides Useful Information On Parkinson’s; Leviticus’ Wireless LVAD Power System Shows Promise In First Patients
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 1 through Feb. 10, includes published results from trials of Global Kinetics’ Personal KinetiGraph movement recording system for Parkinson’s disease patients, Milestone Scientific’s CompuFlo Epidural System for epidural-block anesthesia, and Leviticus Cardio’s wireless Coplanar Energy Transfer system for left-ventricular assist devices.
The Australian company Global Kinetics has developed the Personal KinetiGraph, which includes a wearable smartwatch and a cloud-based system for continuous monitoring of Parkinson's disease symptoms to help improve patient management. KinetiGraph is 510(k)-cleared and CE marked, but the APPRISE multi-center trial will test the system’s ability to improve outcomes. The company hopes to convince US payers to cover it.